YCBD cbdMD, Inc.
Perfumes, Cosmetics & Other Toilet Preparations · NYSE · SEC CIK 1644903 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-90.8%
TTM EPS YoY—
Revenue 3-yr CAGR-7.3%
Net income 3-yr CAGR—
Margins
Gross margin57.7%
Operating margin-13.9%
Net margin-13.8%
FCF margin-11.5%
EBITDA margin-12.8%
Returns
ROE-40.3%
ROA-25.1%
ROIC (approx.)-41.2%
Asset turnover1.82x
Leverage & solvency
Liabilities / assets37.5%
Debt / equity0.00x
Current ratio2.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $19.19M | $19.48M | $24.16M | $35.40M | $44.48M |
| Cost of revenue | $7.22M | $7.49M | $9.18M | $13.07M | $14.50M |
| Gross profit | $11.97M | $12.00M | $14.98M | $22.34M | $29.99M |
| Operating income | -$2.16M | -$3.32M | -$22.49M | -$78.27M | -$19.62M |
| Pretax income | -$2.04M | -$3.70M | -$22.94M | -$70.08M | -$24.29M |
| Income tax | $0 | $0 | $0 | $0 | -$895,000 |
| Net income | -$2.04M | -$3.70M | -$22.94M | -$70.08M | -$23.39M |
| EBITDA | -$1.80M | -$2.86M | -$22.08M | -$77.32M | -$18.60M |
| EPS (basic) | -1.09 | -14.29 | -13.32 | -55.80 | -0.47 |
| EPS (diluted) | -1.09 | -14.29 | -13.32 | -55.80 | -0.47 |
| Weighted avg. shares (diluted) | 4.02M | 539,069 | 2.02M | 1.33M | 54.94M |
| Banking | |||||
| Net interest income | $34,308 | -$29,507 | $63,702 | $16,246 | -$28,930 |
| Balance sheet | |||||
| Cash & equivalents | $2.26M | $2.45M | $1.80M | $6.72M | $26.41M |
| Short-term investments | — | — | — | $0 | $33,351 |
| Receivables | $786,449 | $621,678 | $1.22M | $273,451 | — |
| Inventory | $2.95M | $2.52M | $4.24M | $4.77M | $5.57M |
| Current assets | $6.55M | $6.39M | $8.07M | $16.01M | $36.50M |
| PP&E, net | $277,377 | $454,268 | $716,579 | $823,310 | $2.56M |
| Goodwill | $0 | — | $0 | $0 | $56.67M |
| Intangibles | $2.12M | $2.89M | $3.22M | $17.83M | $23.00M |
| Total assets | $10.42M | $10.58M | $16.20M | $40.79M | $124.88M |
| Current liabilities | $3.19M | $8.62M | $4.67M | $5.29M | $6.92M |
| Long-term debt | — | — | $9 | $125,491 | $108,985 |
| Total debt | — | — | $9 | $125,491 | $108,985 |
| Total liabilities | $3.19M | $8.62M | $7.16M | $9.37M | $21.74M |
| Shareholders' equity | $7.23M | $1.96M | $9.03M | $31.42M | $103.14M |
| Net debt | — | — | -$1.80M | -$6.59M | -$26.30M |
| Shares outstanding | 8.92M | 492,383 | 2.96M | 1.35M | 57.78M |
| Cash flow statement | |||||
| Operating cash flow | -$1.45M | -$352,792 | -$4.30M | -$14.97M | -$14.09M |
| Capital expenditure | $184,172 | $190,015 | $297,549 | $688,680 | $342,013 |
| Free cash flow | -$1.64M | -$542,807 | -$4.60M | -$15.66M | -$14.44M |
| Investing cash flow | -$184,172 | -$290,015 | $702,451 | -$688,680 | -$2.55M |
| Financing cash flow | $1.45M | $1.30M | -$1.32M | -$4.04M | $28.23M |
| Depreciation & amortization | $361,063 | $452,326 | $404,280 | $948,962 | $1.02M |
| Stock-based compensation | — | — | — | — | $1.30M |
| Dividends paid | — | — | — | — | $2.55M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.